Bausch Health Canada has successfully listed its PrOKEDI dosages in the RAMQ formulary, marking a significant step in improving access to schizophrenia treatment for Quebec residents. This move follows recent negotiations with the pan-Canadian Pharmaceutical Alliance.
On July 6, Bausch Health Canada announced that its PrOKEDI 75mg and 100mg dosages have been included in Quebec's Régie de l'assurance maladie du Québec (RAMQ) formulary. This listing is not only a major milestone for the company but also a crucial development for patients seeking effective treatment options for schizophrenia. With this approval, Bausch Health aims to enhance access to PrOKEDI through public drug programs across Canada.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Bausch Health Companies Inc
BHC.TO
BHC.TO
Bausch Health Companies Inc
WealthAwesomeMarket cap
$2.53B
52W high
$11.97
52W low
$6.45
1W change
-2.73%
Beta
0.42
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to rise 3.5% over the next 12 months.
Consensus
No RatingAvg. Target
C$7.01
+3.5% Upside
Current Price
C$6.77
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
49.8%
Annualized
90-Day Vol
42.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$5.66
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$6.38 | C$5.37 – C$7.57 |
| 60 trading days | C$6.01 | C$4.71 – C$7.66 |
| 90 trading days | C$5.66 | C$4.21 – C$7.63 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: This development highlights Bausch Health's commitment to expanding its market presence in Canada, which could positively impact its long-term growth prospects.
What the RAMQ Listing Means for Bausch Health's Valuation
Bausch Health's forward P/E ratio of 1.09x suggests that the market is pricing in significant uncertainty about its future earnings. However, with the recent RAMQ listing, there may be an opportunity for the company to improve its financial outlook if PrOKEDI gains traction in the public drug programs.
Bull case
Potential for increased market access: The RAMQ listing could significantly boost PrOKEDI's presence in Quebec. Bausch Health is working on securing similar agreements in other provinces, which could lead to broader adoption of its product. As public drug programs expand access, more patients may benefit from PrOKEDI, driving revenue growth. The company's focus on innovative treatment options positions it well in the competitive healthcare landscape.
Bear case
Challenges in execution and competition: While the RAMQ listing is a positive step, the company faces challenges with complex provincial reimbursement processes to achieve access across Canada. Bausch Health also competes with other pharmaceutical companies in the schizophrenia treatment market, which could limit its share. Additionally, ongoing financial struggles, indicated by a negative profit margin and low EPS, may impact the company's ability to invest in marketing and distribution for PrOKEDI.
The Significance of RAMQ Listing for Bausch Health
The inclusion of PrOKEDI in the RAMQ formulary is a critical development for Bausch Health, as it allows the company to provide an essential treatment option for adults with schizophrenia. This injectable medication offers rapid therapeutic effects and sustained release, making it a valuable addition to the treatment landscape. The RAMQ listing not only signifies a regulatory win but also opens doors for reimbursement, which is crucial for patient access.
Navigating Provincial Drug Coverage in Canada
Following the RAMQ listing, Bausch Health aims to replicate this success across other provinces. Each province has its own drug coverage processes, which can complicate the rollout of new medications. The company's commitment to working with provincial authorities indicates a strategic approach to expanding access to PrOKEDI, potentially leading to increased sales and market share in the Canadian healthcare system.
Market Implications and Future Outlook
As Bausch Health continues to secure listings and negotiate with provincial drug programs, the market will be watching closely. The success of PrOKEDI could serve as a catalyst for the company's recovery and growth, especially given its current low valuation metrics. Investors should consider how these developments may influence Bausch Health's long-term financial health and market position.
Advertisement
